Overview
Compare with CERUS CORP, LEMAITRE VASCULAR INC or TREACE MEDICAL CONCEPTS, INC., or pick any stock.
- TickerKIDS on Nasdaq1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersWarsaw, Indiana1
- Business address2850 Frontier Drive, Warsaw, In 465822
- Filer categoryAccelerated filer2
See how the biggest companies compare on our leaderboards
OrthoPediatrics Corp. (the "Company") is a Delaware corporation, headquartered in Warsaw, Indiana, and organized in November 2007. The Company’s Common Stock is traded on the Nasdaq Global Market under the symbol KIDS. OrthoPediatrics Corp. is a medical device company committed to designing, developing and marketing anatomically appropriate implants, instruments and specialized braces for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. Initially organized as an Indiana limited liability company on August 31, 2006, OrthoPediatrics Corp. was converted to a Delaware corporation on November 30, 2007. We sell our specialized products, including PediLoc ® , PediPlates ® , Cannulated Screws, PediFlex TM nail, PediNail TM , PediLoc ® Tibia, ACL Reconstruction System…4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
73.1%Gross margin5
-16.6%Operating margin5
-16.8%Net margin5
15.4%Revenue growth, 20255
-11.4%Return on equity5
0.29×Debt to equity5
-$16.0MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Trauma and Deformity brought in 70% of the revenue ORTHOPEDIATRICS CORP broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Trauma and Deformity | $106.8M | $145.1M | $166.3M |
| Spine | $37.9M | $55.2M | $66.0M |
| Sports Medicine And Other | $4.0M | $4.4M | $4.0M |
Regions
United States brought in 79% of the revenue ORTHOPEDIATRICS CORP broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $111.0M | $161.2M | $186.4M |
| Outside the United States | $37.7M | $43.6M | $49.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue27¢$63.7M
- Research and development4¢$9.1M
- Other costs69¢$163.1M
- Income tax0¢$460.0K
Out of $236.3M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net revenue | $236.3M | $204.7M | $148.7M |
| Cost of revenue | $63.7M | $56.1M | $37.5M |
| Gross profit | $172.7M | $148.6M | $111.3M |
| Sales and marketing | $72.7M | $64.3M | $52.8M |
| General and administrative | $119.8M | $102.8M | $73.3M |
| Intangible asset impairment | $4.6M | ||
| Restructuring | $5.6M | $3.7M | $0 |
| Research and development | $9.1M | $11.0M | $10.9M |
| Total operating expenses | $211.9M | $183.6M | $138.0M |
| Operating loss | -$39.2M | -$35.0M | -$26.8M |
| Interest expense (income), net | $6.0M | $2.6M | -$198.0K |
| Loss on early extinguishment of debt | $0 | $3.2M | $0 |
| Fair value adjustment of contingent consideration | $0 | $0 | -$3.0M |
| Other (income) expense | -$6.0M | $1.1M | -$2.3M |
| Total other (income) expenses, net | -$50.0K | $6.9M | -$5.4M |
| Net loss before income taxes | -$39.2M | -$41.9M | -$21.3M |
| Income tax expense (benefit) | $460.0K | -$4.1M | -$338.0K |
| Net loss | -$39.6M | -$37.8M | -$21.0M |
| Basic (in shares) | 23.5M shares | 23.1M shares | 22.7M shares |
| Diluted (in shares) | 23.5M shares | 23.1M shares | 22.7M shares |
| Basic (in dollars per share) | -$1.69 | -$1.64 | -$0.92 |
| Diluted (in dollars per share) | -$1.69 | -$1.64 | -$0.92 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash | $19.6M | $43.8M | ||
| Restricted cash | $625.0K | $2.0M | ||
| Short-term investments | $41.3M | $25.0M | ||
| Accounts receivable - trade, net of allowances of $1,501 and $1,145, respectively | $53.8M | $42.4M | ||
| Inventories, net | $133.8M | $117.0M | ||
| Prepaid expenses and other current assets | $5.9M | $7.0M | ||
| Total current assets | $256.4M | $237.2M | ||
| Property and equipment, net | $49.6M | $50.6M | ||
| Amortizable intangible assets, net | $64.8M | $64.4M | ||
| Goodwill | $109.3M | $93.8M | ||
| Other intangible assets | $12.9M | $16.8M | ||
| Other non-current assets | $15.7M | $10.4M | ||
| Total other assets | $202.7M | $185.4M | ||
| Total assets | $508.6M | $473.2M | ||
| Accounts payable - trade | $18.8M | $8.9M | ||
| Accrued compensation and benefits | $13.7M | $13.9M | ||
| Current portion of long-term debt with affiliate | $170.0K | $160.0K | ||
| Current portion of acquisition installment payable | $2.2M | $1.3M | ||
| Other current liabilities | $11.4M | $9.7M | ||
| Total current liabilities | $46.2M | $34.0M | ||
| Long-term convertible note | $48.5M | $47.9M | ||
| Other long-term debt, net of current portion | $2.9M | $635.0K | ||
| Acquisition installment payable, net of current portion | $2.9M | $2.5M | ||
| Deferred income taxes | $3.6M | $3.4M | ||
| Other long-term liabilities | $9.5M | $5.9M | ||
| Total long-term liabilities | $115.8M | $84.7M | ||
| Total liabilities | $162.0M | $118.6M | ||
| Common stock, $0.00025 par value; 50,000,000 shares authorized; 25,093,792 shares and 24,217,508 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $6.0K | $6.0K | ||
| Additional paid-in capital | $622.3M | $600.9M | ||
| Accumulated deficit | -$275.2M | -$235.6M | ||
| Accumulated other comprehensive loss | -$523.0K | -$10.8M | ||
| Total stockholders' equity | $346.6M | $354.6M | $377.0M | $378.6M |
| Total liabilities and stockholders' equity | $508.6M | $473.2M | ||
| Allowance for doubtful accounts | $1.5M | $1.1M | $1.4M | $1.1M |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 50.0M shares | 50.0M shares | ||
| Common stock, shares issued (in shares) | 25.1M shares | 24.2M shares | ||
| Common stock, shares outstanding (in shares) | 25.1M shares | 24.2M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash | $19.6M | $43.8M | ||
| Restricted cash | $625.0K | $2.0M | ||
| Short-term investments | $41.3M | $25.0M | ||
| Accounts receivable - trade, net of allowances of $1,501 and $1,145, respectively | $53.8M | $42.4M | ||
| Inventories, net | $133.8M | $117.0M | ||
| Prepaid expenses and other current assets | $5.9M | $7.0M | ||
| Total current assets | $256.4M | $237.2M | ||
| Property and equipment, net | $49.6M | $50.6M | ||
| Amortizable intangible assets, net | $64.8M | $64.4M | ||
| Goodwill | $109.3M | $93.8M | ||
| Other intangible assets | $12.9M | $16.8M | ||
| Other non-current assets | $15.7M | $10.4M | ||
| Total other assets | $202.7M | $185.4M | ||
| Total assets | $508.6M | $473.2M | ||
| Accounts payable - trade | $18.8M | $8.9M | ||
| Accrued compensation and benefits | $13.7M | $13.9M | ||
| Current portion of long-term debt with affiliate | $170.0K | $160.0K | ||
| Current portion of acquisition installment payable | $2.2M | $1.3M | ||
| Other current liabilities | $11.4M | $9.7M | ||
| Total current liabilities | $46.2M | $34.0M | ||
| Long-term convertible note | $48.5M | $47.9M | ||
| Other long-term debt, net of current portion | $2.9M | $635.0K | ||
| Acquisition installment payable, net of current portion | $2.9M | $2.5M | ||
| Deferred income taxes | $3.6M | $3.4M | ||
| Other long-term liabilities | $9.5M | $5.9M | ||
| Total long-term liabilities | $115.8M | $84.7M | ||
| Total liabilities | $162.0M | $118.6M | ||
| Common stock, $0.00025 par value; 50,000,000 shares authorized; 25,093,792 shares and 24,217,508 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $6.0K | $6.0K | ||
| Additional paid-in capital | $622.3M | $600.9M | ||
| Accumulated deficit | -$275.2M | -$235.6M | ||
| Accumulated other comprehensive loss | -$523.0K | -$10.8M | ||
| Total stockholders' equity | $346.6M | $354.6M | $377.0M | $378.6M |
| Total liabilities and stockholders' equity | $508.6M | $473.2M | ||
| Allowance for doubtful accounts | $1.5M | $1.1M | $1.4M | $1.1M |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 50.0M shares | 50.0M shares | ||
| Common stock, shares issued (in shares) | 25.1M shares | 24.2M shares | ||
| Common stock, shares outstanding (in shares) | 25.1M shares | 24.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$39.6M | -$37.8M | -$21.0M |
| Goodwill and other intangible asset impairments | $6.5M | $1.8M | $985.0K |
| Depreciation and amortization | $21.1M | $19.1M | $17.4M |
| Loss on early extinguishment of debt | $0 | $3.2M | $0 |
| Stock-based compensation | $17.8M | $13.5M | $10.5M |
| Fair value adjustment of contingent consideration | $0 | $0 | -$3.0M |
| Accretion of acquisition installment payable | $89.0K | $661.0K | $1.4M |
| Deferred income taxes | -$153.0K | -$4.7M | -$1.2M |
| Non-cash other | $244.0K | $90.0K | $0 |
| Accounts receivable - trade | -$9.4M | -$4.7M | -$9.7M |
| Inventories | -$8.5M | -$13.2M | -$26.3M |
| Prepaid expenses and other current assets | $414.0K | -$1.6M | $94.0K |
| Accounts payable - trade | $8.2M | -$4.3M | $1.5M |
| Accrued expenses and other liabilities | $1.2M | $537.0K | $6.9M |
| Other | -$2.8M | $315.0K | -$4.6M |
| Net cash used in operating activities | -$4.9M | -$27.0M | -$27.0M |
| Acquisition of Boston O&P, net of cash acquired | $0 | -$20.2M | $0 |
| Other acquisitions, including clinics, net of cash acquired | -$15.5M | -$2.9M | $0 |
| Acquisition of MedTech, net of cash acquired | $0 | $0 | -$3.1M |
| Acquisition of Rhino assets | $0 | $0 | -$546.0K |
| Sale of short-term marketable securities | $0 | $49.9M | $112.9M |
| Purchase of short-term marketable securities | -$15.0M | -$25.0M | -$48.6M |
| Investment in private companies and purchases of licenses | -$2.0M | -$647.0K | -$2.1M |
| Purchases of property and equipment | -$11.1M | -$14.3M | -$16.9M |
| Net cash (used in) provided by investing activities | -$43.6M | -$13.2M | $41.7M |
| Proceeds from issuance of debt | $25.0M | $73.5M | $9.4M |
| Payment of debt issuance costs | $0 | -$3.4M | $0 |
| Proceeds from exercise of stock options | $0 | $0 | $21.0K |
| Payments on mortgage notes | -$158.0K | -$152.0K | -$144.0K |
| Payment on debt | $0 | -$12.2M | $0 |
| Net cash provided by financing activities | $24.0M | $53.1M | $7.3M |
| Effect of exchange rate changes on cash | $348.0K | -$175.0K | $633.0K |
| NET (DECREASE) INCREASE IN CASH AND RESTRICTED CASH | -$24.2M | $12.8M | $22.6M |
| Cash paid for interest | $6.5M | $2.8M | $42.0K |
| Transfer of instruments between property and equipment and inventory | $279.0K | $420.0K | $57.0K |
| Capital contribution associated with reclassification of liability to equity | $2.1M | ||
| Debt issuance costs not yet paid | $0 | $0 | $127.0K |
No quarter-by-quarter statement was filed.
Corporate structure
ORTHOPEDIATRICS CORP sits at the top of its group. 33 entities, 9 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of ORTHOPEDIATRICS CORP
- Squadron Capital LLC Filed SCHEDULE 13D/A on ORTHOPEDIATRICS CORP, latest Sep 11, 2026 (4 filings since Aug 17, 2022)
- INTEGRATED CORE STRATEGIES (US) LLC Filed SCHEDULE 13G/A on ORTHOPEDIATRICS CORP, latest Jul 15, 2026 (2 filings since Nov 4, 2025)
- BROWN CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G/A on ORTHOPEDIATRICS CORP, latest Nov 12, 2025 (8 filings since Feb 14, 2022)
- BlackRock Filed SC 13G on ORTHOPEDIATRICS CORP, latest Nov 8, 2024 (2 filings since Oct 22, 2024)
- BROWN ADVISORY INC Filed SC 13G/A on ORTHOPEDIATRICS CORP, latest Feb 9, 2024 (3 filings since Feb 7, 2022)
- RIVERBRIDGE PARTNERS LLC Filed SC 13G/A on ORTHOPEDIATRICS CORP, latest Feb 8, 2023 (2 filings since Jan 21, 2022)
- ORTHOPEDIATRICS CORP Warsaw, Indiana
- ApiFix Ltd. Subsidiary · Israel
- Boston Brace International, Inc. Subsidiary · Massachusetts, United States
- C-Pro Direct Holdings Limited Subsidiary · United Kingdom
- C-Pro Direct Ireland Ltd. Subsidiary · Ireland
- C-Pro Direct Ltd. Subsidiary · United Kingdom
- Dynamic Orthopedics, Inc. Subsidiary · Florida, United States
- FollowMed Distribuidora de Produtos Medicos Ltda Subsidiary · Brazil
- FollowMed Sul Distribuidora de Produtos Medicos Ltda Subsidiary · Brazil
- Implant Safe Tech Ltda. Subsidiary · Brazil
- MacyOP, LLC Subsidiary · Connecticut, United States
- MD International, Inc. Subsidiary · Iowa, United States
- MD Orthopaedics, Inc. Subsidiary · Iowa, United States
- Medtech Concepts, LLC Subsidiary · Delaware, United States
- New Ireland Orthotic Services Limited Subsidiary · Ireland
- OP EU B.V. Subsidiary · Netherlands
- OP Netherlands B.V. Subsidiary · Netherlands
- Orthex, LLC Subsidiary · Florida, United States
- OrthoPediatrics AUS PTY LTD Subsidiary · Australia
- OrthoPediatrics Canada ULC d/b/a Pega Medical Subsidiary · Canada
- OrthoPediatrics do Brasil Ltda. Subsidiary · Brazil
- OrthoPediatrics EU Limited Subsidiary · United Kingdom
- OrthoPediatrics GP LLC Subsidiary · Delaware, United States
- OrthoPediatrics Iowa Holdco, Inc. Subsidiary · Delaware, United States
- OrthoPediatrics NZ LTD Subsidiary · New Zealand
- OrthoPediatrics US Distribution Corp. Subsidiary · Delaware, United States
- and 7 more
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What ORTHOPEDIATRICS CORP reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $107.4M5 Dec 31, 2025 | $96.7M5 Dec 31, 2024 | +11.1% |
| Accumulated depreciation | $57.9M5 Dec 31, 2025 | $46.1M5 Dec 31, 2024 | +25.5% |
| Property and equipment, net | $49.6M5 Dec 31, 2025 | $50.6M5 Dec 31, 2024 | −2.1% |
| Operating-lease assets (leased space) | $12.0M5 Dec 31, 2025 | $8.2M5 Dec 31, 2024 | +46.3% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $19.6M5 Dec 31, 2025 | $43.8M5 Dec 31, 2024 | −55.4% |
| Marketable securities, current | $41.3M5 Dec 31, 2025 | $25.0M5 Dec 31, 2024 | +65.1% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $109.3M5 Dec 31, 2025 | $93.8M5 Dec 31, 2024 | +16.4% |
| Indefinite-lived intangibles (excluding goodwill) | $12.9M5 Dec 31, 2025 | $16.8M5 Dec 31, 2024 | −22.9% |
| Finite-lived intangibles, gross | $102.7M5 Dec 31, 2025 | $93.7M5 Dec 31, 2024 | +9.7% |
| Accumulated amortization | $37.9M5 Dec 31, 2025 | $29.2M5 Dec 31, 2024 | +29.8% |
| Finite-lived intangibles, net | $64.8M5 Dec 31, 2025 | $64.4M5 Dec 31, 2024 | +0.6% |
Inventory
Properties, in its own words
We own and occupy approximately 42,000 square feet of office space in Warsaw, Indiana, following expansions of our existing warehouse facilities in 2018 and again in 2021. As a part of its acquisition of MD Ortho, in April 2022, the Company owns over 20,000 square feet of manufacturing and office space in Iowa, which it currently operates and occupies. We also lease approximately 9,000 square feet of warehouse and office space in Canada associated with the Pega acquisition in July 2022. Following our acquisition of Boston Brace in 2024, we own and lease approximately 85,000 square feet of office and manufacturing space in Boston and around the United States and lease approximately 10,000 of clinic space throughout the United States and one clinic in Ireland. We also lease approximately 5,000 square fee of manufacturing and office space in the UK to support our bracing products. In addition, the Company maintains an office in each of Israel, Brazil, and the UK; warehouses in Germany, the Netherlands, Brazil, and Australia and several flex office spaces in Europe, which allow us access to office space when needed. We believe our current facilities are suitable and adequate to meet our current needs. We may add new facilities or expand existing facilities as we add employees, and we believe suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations.
Item 2 of the 10-K filed Mar 4, 2026.4
Leadership
Who has led ORTHOPEDIATRICS CORP, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
20202025
- Chief executive officerDavid R. Bailey Dec 30, 2021 to now14
- Chief executive officerMark C. Throdahl Oct 11, 2017 to Mar 3, 202115
- PresidentGregory A. Odle Mar 15, 2023 to now16
- PresidentDavid R. Bailey Mar 3, 2021 to Mar 15, 202317
- PresidentMark C. Throdahl Oct 11, 2017 to Feb 9, 202115
- Chief financial officerFred Hite Oct 12, 2017 to now18
- Chief operating officerFred Hite Mar 3, 2021 to now19
Board members and other officers (17)
- Sr VP & GM Trauma & DeformityJoseph W. Hauser Mar 3, 2022 to now20
- Executive Vice PresidentDavid R. Bailey Oct 11, 2017 to May 21, 202021
- Executive Vice PresidentGregory A. Odle Oct 11, 2017 to Mar 7, 202322
- Board memberKelly Laine Fischer Nov 12, 2025 to now23
- Board memberGeorge Sinclair Mitchell Dyer May 19, 2023 to now24
- Board memberDavid R. Bailey Mar 3, 2022 to now25
- Board memberSamuel D. Riccitelli Mar 2, 2018 to now26
- Board memberBernie B. Berry Iii. Oct 11, 2017 to Nov 4, 202127
- Board memberBryan W. Hughes Oct 11, 2017 to now28
- Board memberDavid R. Pelizzon Oct 11, 2017 to now29
- Board memberHarold Ruf Oct 11, 2017 to now30
- Board memberKevin Unger Oct 11, 2017 to Jun 3, 202231
- Board memberMark C. Throdahl Oct 11, 2017 to now15
- Board member(reynolds) Marie C. Infante Oct 11, 2017 to now32
- Board memberTerry D. Schlotterback Oct 11, 2017 to now33
- Board memberFred Hite Oct 12, 2017 to now18
- General counselDaniel J. Gerritzen Oct 11, 2017 to now34
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- ApiFix Ltd. Israel3
- Boston Brace International, Inc. Massachusetts3
- C-Pro Direct Holdings Limited United Kingdom3
- C-Pro Direct Ireland Ltd. Ireland3
- C-Pro Direct Ltd. United Kingdom3
- Dynamic Orthopedics, Inc. Florida3
- FollowMed Distribuidora de Produtos Medicos Ltda Brazil3
- FollowMed Sul Distribuidora de Produtos Medicos Ltda Brazil3
- Implant Safe Tech Ltda. Brazil3
- MD International, Inc. Iowa3
- MD Orthopaedics, Inc. Iowa3
- MacyOP, LLC Connecticut3
- Medtech Concepts, LLC Delaware3
- New Ireland Orthotic Services Limited Ireland3
- OP EU B.V. Netherlands3
- OP Netherlands B.V. Netherlands3
- Orthex, LLC Florida3
- OrthoPediatrics AUS PTY LTD Australia3
- OrthoPediatrics Canada ULC d/b/a Pega Medical Canada3
- OrthoPediatrics EU Limited United Kingdom3
- OrthoPediatrics GP LLC Delaware3
- OrthoPediatrics GmbH Germany3
- OrthoPediatrics Iowa Holdco, Inc. Delaware3
- OrthoPediatrics NZ LTD New Zealand3
All 33 listed subsidiaries
- OrthoPediatrics US Distribution Corp. Delaware3
- OrthoPediatrics US L.P. Delaware3
- OrthoPediatrics do Brasil Ltda. Brazil3
- Orthotic Specialists, Inc. Arizona3
- Pediatrics Specialists - Colorado, LLC Colorado3
- Plagio Prevention, LLC Massachusetts3
- Royal Orthotics, LLC North Carolina3
- Telos Partners, LLC Colorado3
- Vilex in Tennessee, Inc. Tennessee3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Aug 4, 20268-K Results of operations35
- Aug 4, 20268-K Regulation FD disclosure36
- Jun 4, 20268-K Shareholder vote37
- Apr 30, 20268-K Results of operations38
- Apr 30, 20268-K Regulation FD disclosure39
- Apr 1, 20268-K Entered a material agreement; New debt or obligation40
- Feb 26, 20268-K Results of operations41
- Feb 26, 20268-K Regulation FD disclosure42
- Jan 12, 20268-K Results of operations43
- Jan 12, 20268-K Regulation FD disclosure44
- Oct 28, 20258-K Results of operations45
- Oct 28, 20258-K Regulation FD disclosure46
- Dec 30, 2021New chief executive David R. Bailey becomes CEO14
- Oct 11, 2017New chief executive Mark C. Throdahl becomes CEO15
Calendar
Coming up
- Oct 27, 2026 · After the closeReports results for the quarter ending Sep/2026 A year earlier it reported ($0.24) a share, on Oct 28, 2025.47
When it reported results
- Aug 4, 2026Reported quarterly or annual results35
- Apr 30, 2026Reported quarterly or annual results38
- Feb 26, 2026Reported quarterly or annual results41
- Jan 12, 2026Reported quarterly or annual results43
- Oct 28, 2025Reported quarterly or annual results45
- Oct 9, 2025Reported quarterly or annual results48
- Aug 5, 2025Reported quarterly or annual results49
- May 7, 2025Reported quarterly or annual results50
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
294 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 75 major events, 141 insider forms, 24 large holders, 34 other. The latest 20:
- Sep 11, 2026SCHEDULE 13D/A EDGAR
- Sep 11, 20264 EDGAR
- Sep 11, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 4, 20264 EDGAR
- Sep 4, 20264 EDGAR
- Sep 4, 20264 EDGAR
- Sep 1, 20264 EDGAR
- Sep 1, 20264 EDGAR
- Sep 1, 2026SCHEDULE 13D/A EDGAR
- Sep 1, 20264 EDGAR
- Aug 26, 20264 EDGAR
- Aug 26, 20264 EDGAR
- Aug 26, 20264 EDGAR
- Aug 24, 2026144 EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 4, 20268-K EDGAR
- Aug 4, 20268-K EDGAR
- Jul 15, 2026SCHEDULE 13G/A EDGAR
- Jun 10, 20264 EDGAR
The 294 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
64 open-market trades by officers, directors and large owners since October 2021: 5 buys and 59 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Pelizzon David RDirector | Sale | 302,369 | $21.01 | $6.4M | Form 4 |
| Sep 10, 2026 | Squadron Capital Holdings LLC10% owner | Sale | 302,369 | $21.01 | $6.4M | Form 4 |
| Sep 10, 2026 | Pritzker Jennifer N.10% owner | Sale | 302,369 | $21.01 | $6.4M | Form 4 |
| Sep 2, 2026 | Pelizzon David RDirector | Sale | 22,500 | $23.35 | $525.4K | Form 4 |
| Sep 2, 2026 | Squadron Capital LLC10% owner | Sale | 22,500 | $23.35 | $525.4K | Form 4 |
| Sep 2, 2026 | Pritzker Jennifer N.10% owner | Sale | 22,500 | $23.35 | $525.4K | Form 4 |
| Sep 1, 2026 | Pelizzon David RDirector | Sale | 10,131 | $23.10 | $234.0K | Form 4 |
| Sep 1, 2026 | Squadron Capital Holdings LLC10% owner | Sale | 10,131 | $23.10 | $234.0K | Form 4 |
| Sep 1, 2026 | Pritzker Jennifer N.10% owner | Sale | 10,131 | $23.10 | $234.0K | Form 4 |
| Aug 28, 2026 | Pelizzon David RDirector | Sale | 326,700 | $23.04 | $7.5M | Form 4 |
| Aug 28, 2026 | Squadron Capital Holdings LLC10% owner | Sale | 326,700 | $23.04 | $7.5M | Form 4 |
| Aug 28, 2026 | Pritzker Jennifer N.10% owner | Sale | 326,700 | $23.04 | $7.5M | Form 4 |
| Aug 26, 2026 | Pelizzon David RDirector | Sale | 18,000 | $24.28 | $437.0K | Form 4 |
| Aug 26, 2026 | Pritzker Jennifer N.10% owner | Sale | 18,000 | $24.28 | $437.0K | Form 4 |
| Aug 26, 2026 | Squadron Capital Holdings LLC10% owner | Sale | 18,000 | $24.28 | $437.0K | Form 4 |
| Aug 25, 2026 | Pelizzon David RDirector | Sale | 16,300 | $24.74 | $403.3K | Form 4 |
| Aug 25, 2026 | Pritzker Jennifer N.10% owner | Sale | 16,300 | $24.74 | $403.3K | Form 4 |
| Aug 25, 2026 | Squadron Capital Holdings LLC10% owner | Sale | 16,300 | $24.74 | $403.3K | Form 4 |
| Aug 24, 2026 | Pelizzon David RDirector | Sale | 4,000 | $25.75 | $103.0K | Form 4 |
| Aug 24, 2026 | Pritzker Jennifer N.10% owner | Sale | 4,000 | $25.75 | $103.0K | Form 4 |
All 64 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Squadron Capital LLCSCHEDULE 13D/A, 4 filings Aug 17, 2022 to Sep 11, 202651
- INTEGRATED CORE STRATEGIES (US) LLCSCHEDULE 13G/A, 2 filings Nov 4, 2025 to Jul 15, 202652
- BROWN CAPITAL MANAGEMENT LLCSCHEDULE 13G/A, 8 filings Feb 14, 2022 to Nov 12, 202553
- BlackRockSC 13G, 2 filings Oct 22, 2024 to Nov 8, 202454
- BROWN ADVISORY INCSC 13G/A, 3 filings Feb 7, 2022 to Feb 9, 202455
- RIVERBRIDGE PARTNERS LLCSC 13G/A, 2 filings Jan 21, 2022 to Feb 8, 202356
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | David R. BaileyPresident and Chief Executive Officer | $550.0K | $3.3M57 | |
| 2025 | Fred L. HiteChief Operating Officer and Chief Financial Officer | $501.0K | $2.4M57 | |
| 2025 | Joseph W. HauserPresident of Trauma, Deformity and OPSB | $413.0K | $2.0M57 | |
| 2025 | Gregory A. OdlePresident of Scoliosis | $368.0K | $1.5M57 | |
| 2025 | Daniel J. GerritzenExecutive Vice President (Legal), General Counsel, and Secretary | $368.0K | $1.5M57 | |
| 2024 | David R. BaileyPresident and Chief Executive Officer | $550.0K | $3.7M57 | |
| 2024 | Fred L. HiteChief Operating Officer and Chief Financial Officer | $501.0K | $2.6M57 | |
| 2024 | Joseph W. HauserPresident of Trauma, Deformity and OPSB | $400.0K | $1.7M57 | |
| 2024 | Gregory A. OdlePresident of Scoliosis | $368.0K | $1.6M57 | |
| 2024 | Daniel J. GerritzenExecutive Vice President (Legal), General Counsel, and Secretary | $368.0K | $1.6M57 | |
| 2023 | David R. BaileyPresident and Chief Executive Officer | $500.0K | $2.7M57 | |
| 2023 | Fred L. HiteChief Operating Officer and Chief Financial Officer | $450.0K | $2.0M57 | |
| 2023 | Daniel J. GerritzenExecutive Vice President (Legal), General Counsel, and Secretary | $353.1K | $1.4M57 | |
| 2023 | Gregory A. OdlePresident of Scoliosis | $353.1K | $1.4M57 | |
| 2023 | Joseph W. HauserPresident of Trauma, Deformity and OPSB | $353.1K | $1.4M57 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Brown Advisory Inc | 1,678,983 | $32.1M | 0.0% | +160,965 |
| BlackRock, Inc. | 1,272,714 | $24.3M | 0.0% | +98,668 |
| Braidwell LP | 1,100,370 | $21.1M | 0.8% | No change |
| Granahan Investment Management, LLC | 1,085,964 | $20.8M | 0.7% | +189,223 |
| Millennium Management LLC | 816,830 | $15.6M | 0.0% | −420,069 |
| Wellington Management Group Llp | 794,309 | $15.2M | 0.0% | −93,135 |
| Vanguard Capital Management LLC | 755,624 | $14.5M | 0.0% | +37,448 |
| Soleus Capital Management, L.P. | 732,144 | $14.0M | 0.5% | +116,697 |
| Morgan Stanley | 693,387 | $13.3M | 0.0% | −447,731 |
| Wasatch Advisors LP | 515,677 | $9.9M | 0.1% | +186,357 |
| Nantahala Capital Management, LLC | 484,684 | $9.3M | 0.3% | +285,235 |
| Dimensional Fund Advisors LP | 480,848 | $9.2M | 0.0% | −65,778 |
| Geode Capital Management, LLC | 452,354 | $8.7M | 0.0% | +19,686 |
| State Street Corp | 391,630 | $7.5M | 0.0% | −22,411 |
| Citadel Advisors LLC | 334,651 | $6.4M | 0.0% | +149,258 |
| Roubaix Capital, LLC | 306,564 | $5.9M | 2.1% | +16,517 |
| Goldman Sachs Group Inc | 304,712 | $5.8M | 0.0% | −37,731 |
| AIGH Capital Management LLC | 269,765 | $5.2M | 0.5% | New |
| AWM Investment Company, Inc. | 237,169 | $4.5M | 0.4% | No change |
| Nuveen, LLC | 222,869 | $4.3M | 0.0% | +58,882 |
| Squarepoint Ops LLC | 195,468 | $3.7M | 0.0% | +95,230 |
| DAFNA Capital Management LLC | 189,130 | $3.6M | 0.7% | +93,471 |
| Kennedy Capital Management LLC | 182,871 | $3.5M | 0.1% | −3,450 |
| Vanguard Portfolio Management LLC | 171,268 | $3.3M | 0.0% | +20,970 |
| Tudor Investment Corp Et Al | 170,022 | $3.3M | 0.0% | +1,039 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How ORTHOPEDIATRICS CORP is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARORTHOPEDIATRICS CORP1
- CIK0001425450
- Employer ID (EIN)26-17618334
- Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address2850 Frontier Drive, Warsaw, IN 465821
- Phone574-268-63791
- Shares outstanding26,109,788 as of Aug 4, 202611
- Public float$362.5M as of Jun 30, 20254
- AuditorDeloitte & Touche LLP, Indianapolis, Indiana PCAOB ID 34; it also attests to the company’s internal control over financial reporting4
- On EDGAR sinceJan 28, 20081
- Filings625 in all: 4 (268), 8-K (149), 10-Q (27), 3 (20), SC 13G/A (16), UPLOAD (14), CORRESP (13), 10-K (9)1
All 38 form types
5 (9), DEF 14A (9), DEFA14A (9), SC 13G (9), 144 (8), 424B5 (8), 3/A (6), 8-K/A (6), SCHEDULE 13G/A (6), S-1/A (5), EFFECT (4), D (3), S-3 (3), ARS (2), DRS/A (2), DRSLTR (2), S-3MEF (2), S-8 (2), SC 13D/A (2), SCHEDULE 13D/A (2), 424B4 (1), 8-A12B (1), CERTNAS (1), D/A (1), DEFR14A (1), DRS (1), REGDEX (1), S-1 (1), SC 13D (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (10-K) Mar 4, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 20, 2026
Latest 8-K (8-K) Aug 4, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.00025 par value per share | KIDS | Nasdaq |
From the cover page of the 10-K filed Mar 4, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks ORTHOPEDIATRICS CORP names in Item 1A of its 10-K filed Mar 4, 2026: 73 risks under these headings, as written.4
- Risks Related to Our Financial Condition and Capital Requirements
- We are unable to predict the extent to which widespread health emergencies, such as COVID-19 and respiratory syncytial virus, or RSV, or other pandemics, epidemics and infectious disease outbreaks, may adversely impact our business and financial results.
- Unfavorable economic conditions could adversely affect our business, financial condition or results of operations.
- We are subject to risks of doing business in other countries, including those related to tariffs, trade restrictions and government actions.
- Changes in Medicaid coverage and reimbursement policies may adversely affect our business, financial condition, and results of operations.
- Potential significant political, trade, or regulatory developments may impact our business.
- We have incurred losses in the past and may be unable to achieve or sustain profitability in the future.
- We may be unable to generate sufficient revenue from the commercialization of our products and services to achieve profitability.
- We may need to raise additional capital to fund our existing commercial operations, develop and commercialize new products and expand our operations.
- Our sales volumes and our results of operations may fluctuate over the course of the year.
- Our loan and security agreement with Braidwell LP contains covenants that may restrict our business and financing activities.
- Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.
The other 62 risks
- Our ability to use net operating losses to offset future taxable income may be subject to limitations.
- Our goodwill, intangible assets and fixed assets are subject to potential impairment; we have recorded significant intangible asset impairment charges and may be required to record additional charges to future earnings if our goodwill or remaining intangible assets become impaired.
- Risks Related to Our Business and Strategy
- Our long-term growth depends on our ability to commercialize our products in development and to develop and commercialize additional products through our research and development efforts, and if we fail to do so we may be unable to compete effectively.
- If the quality of our products does not meet the expectations of physicians or patients, then our brand and reputation could suffer and our business could be adversely impacted.
- We operate in a very competitive business environment and if we are unable to compete successfully against our existing or potential competitors, our sales and operating results may be negatively affected and we may not grow.
- We provide implant and instrument sets for the majority of surgeries performed using our products, and maintaining sufficient levels of inventory could consume a significant amount of our resources, reduce our cash flows and lead to inventory impairment charges.
- The provision of loaned instrument sets to our customers may implicate certain federal and state fraud and abuse laws.
- We may seek to grow our business through acquisitions or investments in new or complementary businesses, products or technologies, through the licensing of products or technologies from third parties or other strategic alliances, and the failure to manage acquisitions, investments, licenses or other strategic alliances, or the failure to integrate them with our existing business, could have a material adverse effect on our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense.
- We may be unable to gain the support of leading hospitals and key opinion leaders, which may make it difficult to establish our products as a standard of care and achieve market acceptance.
- We may be unable to maintain adequate working relationships with healthcare professionals.
- We may be unable to successfully demonstrate to orthopedic surgeons the merits of our products compared to those of our competitors.
- If orthopedic surgeons fail to safely and appropriately use our products, or if we are unable to train orthopedic surgeons on the safe and appropriate use of our products, we may be unable to achieve our expected growth.
- If we are unable to convince hospital facilities to approve the use of our products, our sales may decrease.
- We may be unable to successfully expand our sales infrastructure and adequately address our customers’ needs, it could negatively impact sales and market acceptance of our products and we may never generate sufficient revenue to achieve or sustain profitability.
- We lack published long-term data supporting superior clinical outcomes enabled by our products, which could limit sales.
- If coverage and reimbursement from third-party payors for procedures using our products significantly decline, orthopedic surgeons, hospitals and other healthcare providers may be reluctant to use our products and our sales may decline.
- Our employees, consultants, independent sales agencies, stocking distributors or other commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
- Our insurance policies are expensive and protect us only from some business risks, which will leave us exposed to significant uninsured liabilities.
- We bear the risk of warranty claims on our products.
- The proliferation of physician-owned distributorships could result in increased pricing pressure on our products or harm our ability to sell our products to physicians who own or are affiliated with those distributorships.
- Conversion of the Convertible Notes will dilute the ownership interest of existing stockholders or may
- otherwise depress the price of our common stock.
- Provisions in the indenture governing the Convertible Notes could delay or prevent an otherwise beneficial takeover of us.
- Risks Related to Administrative, Organizational and Commercial Operations, and Growth
- We may be unable to manage our anticipated growth effectively, which could make it difficult to execute our business strategy.
- The loss of our senior management or our inability to attract and retain highly skilled salespeople and engineers could negatively impact our business.
- We may be negatively impacted by restructuring initiatives.
- We face risks associated with our international business.
- We could be negatively impacted by violations of applicable anti-corruption laws or violations of our internal policies designed to ensure ethical business practices.
- Our results may be impacted by changes in foreign currency exchange rates.
- Climate change and related legislative and regulatory initiatives may materially affect our business and results of operations.
- We incur significant costs as a result of operating as a public company and our management is required to devote substantial time to public company compliance programs.
- As a public company, we are obligated to maintain proper and effective internal controls over financial reporting and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock.
- We became an accelerated filer, which will impose additional costs on us.
- If we experience significant disruptions in our information technology systems, our business may be adversely affected.
- We may be subject to various litigation claims and legal proceedings.
- If product liability lawsuits are brought against us, our business may be harmed, and we may be required to pay damages that exceed our insurance coverage.
- Our operations are vulnerable to interruption or loss due to natural or other disasters, power loss, strikes and other events beyond our control.
- Risks Related to Regulatory Matters
- Our products and operations are subject to extensive government regulation and oversight both in the United States and abroad, and our failure to comply with applicable requirements, including but not limited to the HDE requirements and MDD/MDR regulations, could harm our business.
- We may not receive the necessary clearances or approvals for our future products, and failure to timely obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business.
- Modifications to our products may require new 510(k) clearances or PMA approvals, and may require us to cease marketing or recall the modified products until clearances are obtained.
- Our products must be manufactured in accordance with federal and state regulations, and we could be forced to recall our installed systems or terminate production if we fail to comply with these regulations.
- The misuse or off-label use of our products may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business.
- Our products may cause or contribute to adverse medical events that we are required to report to the regulatory authorities, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of a regulatory authority, could have a negative impact on us.
- If we or our distributors or other third-parties do not obtain and maintain international regulatory registrations or approvals for our products, we will be unable to market and sell our products outside of the United States.
- Legislative or regulatory reforms in the United States, the United Kingdom or the European Union may make it more difficult and costly for us to obtain regulatory clearances or approvals for our products or to manufacture, market or distribute our products after clearance or approval is obtained.
- We are subject to certain federal, state and foreign fraud and abuse laws, health information privacy and security laws and transparency laws, which, if violated, could subject us to substantial penalties. Additionally, any challenge to or investigation into our practices under these laws could cause adverse publicity and be costly to respond to, and thus could harm our business.
- Healthcare policy changes, including recently enacted legislation reforming the U.S. healthcare system, could harm our cash flows, financial condition and results of operations.
- Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which may be expensive and restrict how we do business.
- Risks Related to Our Reliance on Third Parties
- We rely on a network of third-party independent sales agencies and distributors to market and distribute our products, and if we are unable to maintain and expand this network, we may be unable to generate anticipated sales.
- We rely on third-party contract manufacturers to assemble our products, and a loss or degradation in performance of these contract manufacturers could have a material adverse effect on our business and financial condition.
- Performance issues, service interruptions or price increases by our shipping carriers could adversely affect our business and harm our reputation and ability to provide our services on a timely basis.
- We rely on a limited number of third-party suppliers for the majority of our products and may be unable to find replacements or immediately transition to alternative suppliers.
- Risks Related to Intellectual Property
- If we are unable to adequately protect our intellectual property rights, or if we are accused of infringing on the intellectual property rights of others, our competitive position could be harmed or we could be required to incur significant expenses to enforce or defend our rights.
- Litigation or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and money and could prevent us from selling our products or impact our stock price.
- If we are unable to protect the confidentiality of our trade secrets, our business and competitive position could be harmed.
- We may be unable to enforce our intellectual property rights throughout the world.
- Third parties may assert ownership or commercial rights to inventions we develop.
- Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.
- Risks Related to Ownership of Our Common Stock
- The price of our common stock may be volatile.
- The price of our stock may be vulnerable to manipulation, including through short sales.
- We may be subject to securities litigation, which is expensive and could divert our management’s attention.
- Future sales of our common stock may cause our stock price to decline.
Legal proceedings
From time to time, we are involved in various legal proceedings arising in the ordinary course of our business. A discussion of certain of those legal proceedings is contained in Note 17 – Commitments and Contingencies (under the heading “Legal Proceedings”) of the notes to the consolidated financial statements included in Item 8. Financial Statements of Part II of this Annual Report on Form 10-K, which discussion is incorporated herein by reference.
We are not presently a party to any other legal proceedings the outcome of which, if determined adversely to us, would individually or in the aggregate materially affect our financial position, results of operations or cash flows.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARGregory A. Odle, President
- 17SEC EDGARDavid R. Bailey, President
- 18SEC EDGARFred Hite, Chief financial officer
- 19SEC EDGARFred Hite, Chief operating officer
- 20
- 21
- 22
- 23SEC EDGARKelly Laine Fischer, Board member
- 24
- 25SEC EDGARDavid R. Bailey, Board member
- 26SEC EDGARSamuel D. Riccitelli, Board member
- 27SEC EDGARBernie B. Berry Iii., Board member
- 28SEC EDGARBryan W. Hughes, Board member
- 29SEC EDGARDavid R. Pelizzon, Board member
- 30SEC EDGARHarold Ruf, Board member
- 31SEC EDGARKevin Unger, Board member
- 32
- 33SEC EDGARTerry D. Schlotterback, Board member
- 34SEC EDGARDaniel J. Gerritzen, General counsel
- 35SEC EDGARResults of operations
- 36SEC EDGARRegulation FD disclosure
- 37SEC EDGARShareholder vote
- 38SEC EDGARResults of operations
- 39SEC EDGARRegulation FD disclosure
- 40
- 41SEC EDGARResults of operations
- 42SEC EDGARRegulation FD disclosure
- 43SEC EDGARResults of operations
- 44SEC EDGARRegulation FD disclosure
- 45SEC EDGARResults of operations
- 46SEC EDGARRegulation FD disclosure
- 47NasdaqNasdaq calendar
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57